Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

Loneliness and social isolation have been linked to an elevated risk of non-alcoholic fatty liver disease (NAFLD), according ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...

Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...